Investor Relations

Company Overview

IR-MED Inc.’s patented spectrographic AI-based technology platform brings biomarker profiling to point of care devices. Providing healthcare professionals with non-invasive, skin tone agnostic, real-time data-driven analysis of blood and tissue to identify medical conditions, the Company aims to change treatment paradigms and economics in muti-billion markets.

PressureSafe™️, slated for launch in the first half of 2024, pending regulatory approval, is a handheld decision support device that identifies early-stage pressure injuries with ~90% accuracy, creating a novel solution to a $26.8 billion problem and driving healthcare equality for people of all skin tones. Despite being a highly preventable condition, 2.5 million people get pressure injuries each year. 60,000 deaths annually in the U.S. are directly attributed to pressure injuries, the 2nd most common lawsuit after wrongful death.

IR-MED holds patents protecting its technology and innovations in the noninvasive tissue analysis, and in the modeling and analysis of subcutaneous tissue. Future indications for IR-MED’s technology are planned for additional tissue and skin indications, ear infections, and therapeutic drug monitoring.